Key result
Patients sustaining acute myocardial infarction while on chronic clopidogrel exhibited higher rates of clopidogrel poor responsiveness compared to clopidogrel-naïve patients.
Why the study?
Does acute myocardial infarction occurring during chronic clopidogrel therapy associate with higher platelet reactivity compared to clopidogrel-naïve patients?
Case-Control (n=87)
No
Does acute myocardial infarction occurring during chronic clopidogrel therapy associate with higher platelet reactivity compared to clopidogrel-naïve patients?
Patients presenting with acute myocardial infarction while on chronic clopidogrel therapy have a high incidence of clopidogrel poor responsiveness and stent thrombosis.
Answers are grounded in this paper and cite their sources.
Clopidogrel failure in AMI links to poor responsiveness and stent thrombosis; leaves open whether reactivity testing improves outcomes.
OBJECTIVES: The clinical significance of the laboratory-based phenomenon of clopidogrel hypo-responsiveness and platelet reactivity associated with acute myocardial infarction, despite chronic clopidogrel therapy, is largely unknown. We aimed to determine platelet reactivity and clinical and angiographic features in 29 consecutive patients sustaining an acute myocardial infarction despite chronic (≥1 month) clopidogrel therapy. METHODS: Platelet reactivity was determined on admission using conventional aggregometry. All patients underwent coronary angiography within 24 hours of admission. Patients were matched with clopidogrel-naïve acute myocardial infarction patients. Clopidogrel-naïve patients received a 600 mg clopidogrel loading dose and 75 mg/day thereafter. RESULTS: Of the 29 study patients, 19 (66%) presented with ST-elevation myocardial infarction, and in 25% the infarction was related to angiographically-proved definite stent thrombosis. Two-thirds of these patients were poor responders to clopidogrel (adenosine diphosphate-induced platelet aggregation >50%) and dual antiplatelet poor responsiveness was found in 57% in the chronic clopidogrel therapy group. Compared with clopidogrel-naïve patients, chronic clopidogrel therapy patients were more likely to demonstrate clopidogrel poor responsiveness (66% versus 38%, p = 0.02), to be diabetic (52% versus 33%, p = 0.1) and to have multi-vessel coronary disease (79% versus 55%, p = 0.03). CONCLUSIONS: Patients sustaining acute coronary syndrome despite chronic clopidogrel therapy are more likely to exhibit inadequate platelet inhibition with clopidogrel.
No takes yet. Share an insight, caveat, or question.
Regev et al. (2018) conducted a case-control in Acute myocardial infarction (n=87). Chronic clopidogrel therapy vs. Clopidogrel-naïve was evaluated on Clopidogrel poor responsiveness (ADP-induced platelet aggregation >50%) (p=0.02). Patients sustaining acute myocardial infarction while on chronic clopidogrel exhibited higher rates of clopidogrel poor responsiveness compared to clopidogrel-naïve patients.
Synapse has enriched 10 related papers. Consider them for comparative context: